Bonesupport Holding AB (publ)

BATS-CHIXE:BONEXS Stock Report

Market Cap: SEK 14.5b

Bonesupport Holding Valuation

Is BONEXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BONEXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BONEXS (SEK219.7) is trading below our estimate of future cash flow value (SEK461.05)

Significantly Below Future Cash Flow Value: BONEXS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BONEXS?

Key metric: As BONEXS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BONEXS. This is calculated by dividing BONEXS's market cap by their current earnings.
What is BONEXS's PE Ratio?
PE Ratio67.8x
EarningsSEK 213.91m
Market CapSEK 14.50b

Price to Earnings Ratio vs Peers

How does BONEXS's PE Ratio compare to its peers?

The above table shows the PE ratio for BONEXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.4x
GNS Genus
30.9x-10.68%UK£1.5b
BVXP Bioventix
10.6xn/aUK£78.9m
AREC Arecor Therapeutics
24.7xn/aUK£23.0m
HCM HUTCHMED (China)
111.3x37.47%UK£1.5b
BONEXS Bonesupport Holding
67.8x32.76%SEK 14.5b

Price-To-Earnings vs Peers: BONEXS is expensive based on its Price-To-Earnings Ratio (67.8x) compared to the peer average (44.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does BONEXS's PE Ratio compare vs other companies in the European Biotechs Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies8PE020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BONEXS is expensive based on its Price-To-Earnings Ratio (67.8x) compared to the European Biotechs industry average (18.7x).

Price to Earnings Ratio vs Fair Ratio

What is BONEXS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BONEXS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BONEXS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BONEXS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
SEK 357.25
0%
14.41%SEK 415.00SEK 275.00n/a6
Jul ’27n/a
SEK 371.83
0%
10.11%SEK 416.00SEK 320.00n/a6
Jun ’27SEK 229.60
SEK 373.83
+62.82%
10.73%SEK 428.00SEK 320.00n/a6
May ’27SEK 218.30
SEK 377.17
+72.77%
10.40%SEK 428.00SEK 320.00n/a6
Apr ’27SEK 190.05
SEK 366.60
+92.90%
12.40%SEK 428.00SEK 310.00n/a5
Mar ’27SEK 198.40
SEK 366.60
+84.78%
12.40%SEK 428.00SEK 310.00n/a5
Feb ’27SEK 189.15
SEK 374.60
+98.04%
9.76%SEK 428.00SEK 330.00n/a5
Jan ’27n/a
SEK 391.20
0%
11.30%SEK 471.00SEK 340.00n/a5
Dec ’26SEK 189.15
SEK 391.20
+106.82%
11.30%SEK 471.00SEK 340.00n/a5
Nov ’26SEK 225.20
SEK 391.20
+73.71%
11.30%SEK 471.00SEK 340.00n/a5
Oct ’26n/a
SEK 409.80
0%
9.40%SEK 474.00SEK 370.00n/a5
Sep ’26SEK 316.20
SEK 419.75
+32.75%
8.79%SEK 474.00SEK 375.00n/a4
Aug ’26SEK 338.80
SEK 419.00
+23.67%
8.54%SEK 471.00SEK 375.00n/a4
Jul ’26SEK 282.00
SEK 426.00
+51.06%
7.11%SEK 474.00SEK 400.00n/a4
Jun ’26SEK 255.80
SEK 434.67
+69.92%
6.99%SEK 474.00SEK 400.00SEK 229.603
May ’26SEK 299.80
SEK 434.67
+44.99%
6.99%SEK 474.00SEK 400.00SEK 218.303
Apr ’26SEK 298.80
SEK 445.33
+49.04%
7.92%SEK 486.00SEK 400.00SEK 190.053
Mar ’26n/a
SEK 445.33
0%
7.92%SEK 486.00SEK 400.00SEK 198.403
Feb ’26n/a
SEK 422.33
0%
4.92%SEK 450.00SEK 400.00SEK 189.153
Jan ’26n/a
SEK 402.33
0%
2.77%SEK 417.00SEK 390.00n/a3
Dec ’25n/a
SEK 362.33
0%
16.35%SEK 417.00SEK 280.00SEK 189.153
Nov ’25n/a
SEK 345.67
0%
16.22%SEK 417.00SEK 280.00SEK 225.203
Oct ’25n/a
SEK 323.33
0%
9.56%SEK 350.00SEK 280.00n/a3
Sep ’25SEK 298.80
SEK 323.33
+8.21%
9.56%SEK 350.00SEK 280.00SEK 316.203
Aug ’25n/a
SEK 323.33
0%
9.56%SEK 350.00SEK 280.00SEK 338.803
SEK 356.44
Fair Value
38.4% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/02 17:39
End of Day Share Price 2026/07/15 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bonesupport Holding AB (publ) is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Erik CasselDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie